CDT Stock Chart & Stats
$1.89
-$0.22(-7.03%)
At close: 4:00 PM EDT
$1.89
-$0.22(-7.03%)
Day’s Range― - ―
52-Week Range$1.34 - $44,442.85
Previous Close$2.8
Volume27.53K
Average Volume (3M)6.45M
Market Cap
$1.63M
Enterprise Value$1.08B
Total Cash (Recent Filing)$348.65M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta2.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5669.00
Shares Outstanding1,124,515
10 Day Avg. Volume12,579,608
30 Day Avg. Volume6,454,896
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.48
Enterprise Value/Market Cap663.24
Enterprise Value/Revenue0.75
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda4.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CDT Equity News
CDT FAQ
What was CDT Equity’s price range in the past 12 months?
CDT Equity lowest stock price was $1.34 and its highest was $44442.85 in the past 12 months.
What is CDT Equity’s market cap?
CDT Equity’s market cap is $1.63M.
When is CDT Equity’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CDT Equity’s earnings last quarter?
Currently, no data Available
Is CDT Equity overvalued?
According to Wall Street analysts CDT Equity’s price is currently Overvalued.
Does CDT Equity pay dividends?
CDT Equity does not currently pay dividends.
What is CDT Equity’s EPS estimate?
CDT Equity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CDT Equity have?
CDT Equity has 1,124,515 shares outstanding.
What happened to CDT Equity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CDT Equity?
Currently, no hedge funds are holding shares in CDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CDT Equity
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Technical Analysis
Moleculin Biotech
―
Bone Biologics
―
Silexion Therapeutics
―
Calidi Biotherapeutics
―
Azitra Inc
―
Ownership Overview
29.67% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
70.33% Public Companies and
Individual Investors